Abstract:Prion diseases are a group of rare, fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP(C)) into a self-replicating and proteinase K-resistant conformer, termed scrapie PrP (PrP(Sc)). Aggregates of PrP(Sc) deposited around neurons lead to neuropathological alterations. Currently, there is no effective treatment for these fatal illnesses; thus, the development of an effective therapy is a priority. PrP peptide-based ELISA assay methods were developed for detection and immunoaffinity chromatography capture was developed for purification of naturally occurring PrP peptide autoantibodies present in human CSF, individual donor serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg). The ratio of anti-PrP autoantibodies (PrP-AA) to total IgG was ∼1:1200. The binding epitope of purified PrP-AA was mapped to an N-terminal region comprising the PrP amino acid sequence KTNMK. Purified PrP-AA potently blocked fibril formation by a toxic 21-amino acid fragment of the PrP peptide containing the amino acid alanine to valine substitution corresponding to position 117 of the full-length peptide (A117V). Furthermore, PrP-AA attenuated the neurotoxicity of PrP(A117V) and wild-type peptides in rat cerebellar granule neuron (CGN) cultures. In contrast, IgG preparations depleted of PrP-AA had little effect on PrP fibril formation or PrP neurotoxicity. The specificity of PrP-AA was demonstrated by immunoprecipitating PrP protein in brain tissues of transgenic mice expressing the human PrP(A117V) epitope and Sc237 hamster. Based on these intriguing findings, it is suggested that human PrP-AA may be useful for interfering with the pathogenic effects of pathogenic prion proteins and, thereby has the potential to be an effective means for preventing or attenuating human prion disease progression.

A Panel of Monoclonal Antibodies Against the Prion Protein Proves That There is No Prion Protein in Human Pancreatic Ductal Epithelial Cells

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Production and Characterization of a Monoclonal Antibody Against GRAM Domain-Containing Protein 1A

Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity

Preparations of Specific Antibodies Against PrP N-terminal or C-terminal Peptides and Preliminary Study on Establishment of ELISA Diagnostic Method

Preparation of Monoclonal Antibodies Against Prion Proteins with Full-Length Hamster PrP.

[Establishment of a Prion Disease PrP(Sc) Panel from the Brain Tissues of Experimental Hamsters Infected with Scrapie Agent 263K].

Establishment of A Stable Prpsc Panel from Brain Tissues of Experimental Hamsters with Scrapie Strain 263K

Generation and Identification of Phage Engineering Antibodies Library Against Hamster Prion Protein

Prion Protein and Cancers

PrP(Sc)-specific Antibodies with the Ability to Immunodetect Prion Oligomers.

Generation of Genetic Engineering Monoclonal Antibodies Against Prion Protein

Simple Method of Monoclonal Antibody Production Against Mammalian Cellular Prion Protein

Guanidine hydrochloride extraction and detection of prion proteins in mouse and hamster prion diseases by ELISA

Immunological Characteristics of Anti-PrP McAbs

Expression of a Chimera of Bovine Prion Protein and Yeast Ure2p Prion Domain in Escherichia Coli and Preparation of Monoclonal Antibodies Against Prion Protein

Therapeutic for Prion Diseases with Immunology

Establishment of a Special Platform for the Research of Prion and the Diagnosis of Human Prion Disease - China's Studies

[Analysis of Monoclonal Antibody Binding Sites in Ovine Prion Protein].

PrP Conformational Transitions Alter Species Preference of a PrP-specific Antibody

The Humanization and Maturation of an Anti-PrPc Antibody.